Anaplastic Large Cell Lymphoma
Links shared publicly online about this topic
BREAST IMPLANTS and ALAC ANAPLASTIC LARGE CELL LYMPHOMA
cosmeticsurgery-news.com — “BREAST IMPLANTS and ALAC ANAPLASTIC LARGE CELL LYMPHOMA” View full resource at cosmeticsurgery-news.com
Most Recently Shared on February 7, 2011 at 7:27 pm By:
Kevin M. Johnson, MD Physician, Doctor, and Surgeon
FDA warns about breast implants and rare form of cancer. http://cosmeticsurgery-news.com/article3090.html
Adcetris Approved for Hodgkin lymphoma and Systemic Anaplastic Large Cell Lymphoma - MPR
empr.com — “The FDA approved Adcetris (brentuximab vedotin; Seattle Genetics) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL).” View full resource at empr.com
Most Recently Shared on August 22, 2011 at 2:10 pm By:
Adcetris Approved for Hodgkin lymphoma and Systemic Anaplastic Large Cell Lymphoma http://ow.ly/69lQM #lymphoma #adcetris
Anaplastic Large Cell Lymphoma and Breast Implants - Suresh Koneru, MD
drkoneru.posterous.com — “Anaplastic Large Cell Lymphoma and Breast Implants - Suresh Koneru, MD” View full resource at drkoneru.posterous.com
Most Recently Shared on January 31, 2011 at 4:31 am By:
Suresh Koneru, MD Physician, Doctor, Surgeon, and Plastic Surgeon
Anaplastic Large Cell Lymphoma and Breast Implants http://post.ly/1YTTI
BLA Submitted for Brentuximab Vedotin for Hodgkin and Anaplastic Large Cell Lymphomas - ONA
oncologynurseadvisor.com — “Seattle Genetics announced that it has submitted a Biologics License Application (BLA) to the FDA for the use of brentuximab vedotin (SGN-35) to treat relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.” View full resource at oncologynurseadvisor.com
Most Recently Shared on March 1, 2011 at 5:25 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
BLA Submitted for Brentuximab Vedotin for Hodgkin and Anaplastic Large Cell Lymphomas http://goo.gl/fb/6ZBhe
BLA Submitted for Brentuximab Vedotin for Hodgkin and Anaplastic Large Cell Lymphomas - MPR
empr.com — “Seattle Genetics announced that it has submitted a Biologics License Application (BLA) to the FDA for the use of brentuximab vedotin (SGN-35) to treat relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.” View full resource at empr.com
Most Recently Shared on March 1, 2011 at 5:17 pm By:
MPR News: BLA Submitted for Brentuximab Vedotin for Hodgkin and Anaplastic Large Cell Lymphomas: Seattle Genetic... http://bit.ly/eZo3Yj
Adcetris (Brentuximab Vedotin) Approved For Hodgkin Lymphoma And Systemic Anaplastic Large Cell Lymphoma - FDA
medicalnewstoday.com — “The FDA has approved brentuximab vedotin, brand name Adcetris, for the treatment of HL (Hodgkin lymphoma) and ALCL (systemic anaplastic large cell lymphoma). Adcetris consists of a drug and an ant” View full resource at medicalnewstoday.com
Most Recently Shared on August 19, 2011 at 9:05 pm By:
Adcetris (Brentuximab Vedotin) Approved For Hodgkin Lymphoma And Systemic Anaplastic Large Cell Lymphoma - FDA http://mnt.to/3Z5F
Cutaneous CD30+ (Ki-1) Anaplastic Large-Cell Lymphoma: eMedicine Dermatology
emedicine.medscape.com — “Overview: CD30+ lymphoproliferative disorders include a wide spectrum of disease with lymphomatoid papulosis at the benign end of the spectrum and cutaneous CD30+ anaplastic large-cell lymphomas (ALCLs) at the malignant end. Borderline lesions lie somewhere in between.” View full resource at emedicine.medscape.com
Most Recently Shared on March 2, 2010 at 8:42 pm By:
Medscape Dermatology Health Site
Cutaneous CD30+ anaplastic large-cell lymphoma article updated for 2010: http://bit.ly/c5Gqmy
Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses
fda.gov — “Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses” View full resource at fda.gov
Most Recently Shared on January 26, 2011 at 5:45 pm By:
Focused on Health Health Organization
FDA review shows possible link b/w breast implants & cancer: http://bit.ly/erJ7wj (via @HHSgov)
Breast implants: Doctors organizations react to the FDA study of breast implants and anaplastic large cell lymphoma - latimes.com
latimes.com — “You've no doubt heard about the Food and Drug Administration ’s investigation of the "possible association" between breast implants and a rare form of cancer known as anaplastic large cell lymphoma , or ALCL. And you've heard the media reaction (and possibly concerned friends or relatives or coworkers or...) Now let's hear from the folks who implant those implants.” View full resource at latimes.com
Most Recently Shared on January 29, 2011 at 12:40 am By:
LA Times Health News Health News
Breast implants and 'possible link' to rare cancer -- surgeon associations respond http://lat.ms/dKayaO
FDA reviews possible risk of anaplastic large cell lymphoma (ALCL) with breast implants - ONA
oncologynurseadvisor.com — “The FDA announced a possible association between saline and silicone gel-filled breast implants and anaplastic large cell lymphoma (ALCL).” View full resource at oncologynurseadvisor.com
Most Recently Shared on January 26, 2011 at 7:27 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
FDA reviews possible risk of anaplastic large cell lymphoma (ALCL) with breast implants http://goo.gl/fb/hmq7W
Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma (ALCL) - MPR
empr.com — “Seattle Genetics and Millennium, a wholly owned subsidiary of Takeda, announced results from its Phase 2 trial of brentuximab vedotin (SGN-35) for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).” View full resource at empr.com
Most Recently Shared on October 12, 2010 at 7:25 pm By:
MPR News: Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma (ALCL): Seattle... http://bit.ly/duAZjo
Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma (ALCL) - ONA
oncologynurseadvisor.com — “Seattle Genetics and Millennium, a wholly owned subsidiary of Takeda, announced results from its Phase 2 trial of brentuximab vedotin (SGN-35) for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma (ALCL).” View full resource at oncologynurseadvisor.com
Most Recently Shared on October 12, 2010 at 7:53 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 2 trial of brentuximab vedotin for the treatment of anaplastic large cell lymphoma… http://goo.gl/fb/E1Zk1
Brentuximab wins accelerated approval for HL, anaplastic large cell lymphoma | HemOncToday
hemonctoday.com — “The FDA’s Oncologic Drugs Advisory Committee today unanimously awarded accelerated approvals for IV brentuximab vedotin to treat patient” View full resource at hemonctoday.com
Most Recently Shared on July 14, 2011 at 3:42 pm By:
HemOnc Today Oncology and Health News
"People with Hodgkin's lymphoma will have another option for treating a terrible disease," - Mikkael Sekeres, MD, MS http://bit.ly/pTKjhq
Anaplastic large-cell lymphoma has been observed in women with breast implants. | GreenMedInfo | Article | Natural Medicine | Alternative Medicine | Integrative Medicine | Consumer Advocacy
greenmedinfo.com — “This article on GreenMedInfo.com concerns - Anaplastic large-cell lymphoma in women with breast implants.” View full resource at greenmedinfo.com
Most Recently Shared on January 8, 2012 at 11:22 am By:
A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast has been reported. | GreenMedInfo | Article | Natural Medicine | Alternative Medicine | Integrative Medicine | Consumer Advocacy
greenmedinfo.com — “This article on GreenMedInfo.com concerns - A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast.” View full resource at greenmedinfo.com
Most Recently Shared on January 8, 2012 at 11:28 am By:
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
Kevin M. Johnson, MD
Cosmetic Surgeon Caring physician Teacher
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
Suresh Koneru, MD
Board Certified Plastic Surgeon. Practicing cosmetic and reconstructive surgery.
Advertisement
